Clinical trial
A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
NCT00723983 is registered in ClinicalTrials.gov with NuPathe Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
- Lead sponsor
- NuPathe Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2008
- Completion date
- September 30, 2009
- Enrollment
- 23 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.